US EditionWhy Elite Athletes Like Tom Brady Are Backing GLP-1 Weight-Loss Drugs
2 Articles
2 Articles
The accession of high-performance athletes to the promotion of medicinal products based on GLP-1, commonly known as “emergising cannets”, is growing in the United States and stimulating the visibility of these treatments for obesity and diabetes type 2. The most recent case involves NFL’s former quarterback Tom Brady, named director of welfare of the digital health platform and Med. Emphatic channels are reducing the cost of food in the United S…
Why Elite Athletes Like Tom Brady Are Backing GLP-1 Weight-Loss Drugs
When a seven-time Super Bowl champion becomes the chief wellness officer of a digital health company focused on GLP-1 drugs, it grabs attention for a reason. That is exactly what happened when Tom Brady was named to a leadership role at eMed, a platform that prescribes GLP-1 medications such as Ozempic, Wegovy, and Zepbound. Brady now joins a growing list of elite athletes whose names are being associated with a class of drugs originally designe…
Coverage Details
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
